This is for a non-disease modifying drug - wonder what the price would be for a disease modifying HD drug.
Acorda Therapeutics is gambling $525 million on a Phase III-ready Parkinson's treatment
ACOR is trading up 18% right now...
Acorda Therapeutics is gambling $525 million on a Phase III-ready Parkinson's treatment, striking an all-cash deal to buy Civitas Therapeutics.
Acorda CEO Ron Cohen
Acorda ($ACOR) now has control of CVT-301, a fast-acting rescue formulation of levodopa that can be self-administered through an inhaler. Just weeks ago Civitas nailed down a $55 million venture round from a long lineup of backers, then pivoted to an IPO filing. But that was evidently all part of the bargaining process for this drug, with Acorda settling on an unusual all-cash deal for an experimental program.
and-
"Sales from CVT-301 are expected to exceed $500 million, according to Ron Cohen, Acorda's CEO. Acorda expects to complete another trial and then file for regulatory approval in the U.S. by the end of 2016."
Acorda Therapeutics is gambling $525 million on a Phase III-ready Parkinson's treatment
-
- There are more pages in this discussion • 11 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add ATH (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
0.4¢ |
Change
-0.001(11.1%) |
Mkt cap ! $20.98M | |||
| Open | High | Low | Value | Volume |
| 0.5¢ | 0.5¢ | 0.4¢ | $14.55K | 3.241M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 62 | 71906262 | 0.4¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 0.5¢ | 32338803 | 25 |
View Market Depth
| Last trade - 16.10pm 28/06/2024 (20 minute delay) ? |
| ATH (ASX) Chart |